Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,045 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Congenital Anemias Clear all
Completed Phase 2 Interventional Results available

Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease

NCT05098028
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Low Dose Rifaximin ER, Low Dose Rifaximin DER, High Dose Rifaximin ER, High Dose Rifaximin DER, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Orange, California • Denver, Colorado • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 15, 2026, 8:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer

NCT00540995
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts
Interventions
busulfan, etoposide, intensity-modulated radiation therapy, allogeneic hematopoietic stem cell transplantation, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, tomotherapy
Drug · Radiation · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
6 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 15, 2026, 8:53 AM EDT
Recruiting Not applicable Interventional

Sickle Cell Improvement: Enhancing Care in the Emergency Department

NCT05373771
View directory record Official record
Conditions
Sickle Cell Crisis
Interventions
Care pathway
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 18 Years
Enrollment
5,328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 15, 2026, 8:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Acute Kidney Injury in Patients With Sickle Cell Disease

NCT03105271
View directory record Official record
Conditions
Sickle Cell Disease, Kidney Injury, Kidney Diseases, Kidney Disease, Chronic
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year to 25 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 15, 2026, 8:53 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX)

NCT05810181
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Interview
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
8 Years and older
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 15, 2026, 8:53 AM EDT
Recruiting Not applicable Interventional

Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease

NCT07222475
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Songwriting intervention (active music therapy)
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
11 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 15, 2026, 8:53 AM EDT
Withdrawn Phase 2 Interventional

Dipyridamole/Magnesium To Improve Sickle Cell Hydration

NCT00276146
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
oral dipyridamole, oral magnesium, or a combination of both
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years and older
Timeline
Started 2005
U.S. locations
3
States / cities
Detroit, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 15, 2026, 8:53 AM EDT
Recruiting Phase 2 Interventional

Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults

NCT07369024
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Ketamine Infusion, Pain Management, Vaso-Occlusive Crises
Interventions
Sub-dissociative Ketamine Infusion, Normal Saline Placebo Infusion
Drug
Lead sponsor
Mohsen Saidinejad
Other
Eligibility
5 Years to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 2 Interventional

Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2

NCT03758950
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Placebo, Mometasone
Drug
Lead sponsor
Jeffrey Glassberg
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 15, 2026, 8:53 AM EDT
Recruiting No phase listed Observational

Peripheral Arterial Tonometry and Neurocognition in Sickle Cell Disease

NCT06477289
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years to 25 Years
Enrollment
65 participants
Timeline
2024 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 2 Interventional Results available

Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease

NCT01389024
View directory record Official record
Conditions
Sickle Cell Disease, Stroke
Interventions
Hydroxyurea, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Months to 54 Months
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
5
States / cities
Birmingham, Alabama • Baltimore, Maryland • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 1 Interventional

Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD)

NCT01783691
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
NKTT120
Drug
Lead sponsor
NKT Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
Oakland, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 15, 2026, 8:53 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure

NCT00001962
View directory record Official record
Conditions
Aplastic Anemia, Pure Red Cell Aplasia, Diamond Blackfan Anemia
Interventions
Daclizumab
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 15, 2026, 8:53 AM EDT
Completed No phase listed Observational

Genetics and Pain Severity in Sickle Cell Disease

NCT01441141
View directory record Official record
Conditions
Genotype, Pain, Genetic Variation, Quantitative Sensory Testing (QST), GCH1
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 15, 2026, 8:53 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Blood Collection for Research Related to Certain Diseases Involving Blood Vessels

NCT00047996
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
2
States / cities
Bethesda, Maryland • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 2 Interventional

Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia

NCT00004381
View directory record Official record
Conditions
Glucosephosphate Dehydrogenase Deficiency, Hyperbilirubinemia, Hemolytic Disease of Newborn
Interventions
tin mesoporphyrin
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
0 Years to 24 Hours
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 2 Interventional Results available

Vitamin D for Sickle-cell Respiratory Complications

NCT01443728
View directory record Official record
Conditions
Sickle Cell Disease, Vitamin D Deficiency, Acute Chest Syndrome, Asthma, Respiratory Infections
Interventions
Experimental: Vitamin D3 100,000 IU, Active Comparator: Vitamin D3 12,000 IU
Drug
Lead sponsor
Gary M Brittenham, MD
Other
Eligibility
3 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 15, 2026, 8:53 AM EDT
Active, not recruiting Phase 2 Interventional

Reduced Intensity Transplantation for Severe Sickle Cell Disease

NCT04362293
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus, hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 25 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 15, 2026, 8:53 AM EDT
Not yet recruiting Not applicable Interventional

Hypoxic Red Blood Cells in Sickle Cell Anemia

NCT06743113
View directory record Official record
Conditions
Sickle Cell Anaemia, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Interventions
Hemanext ONE System, Conventional RBCs
Device
Lead sponsor
Hemanext
Industry
Eligibility
7 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Farmington, Connecticut • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Arginine as a Treatment for Sickle Cell Anemia

NCT00513617
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Arginine, Placebo
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
5 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
17
States / cities
Oakland, California • San Francisco, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 2Phase 3 Interventional

A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

NCT03655678
View directory record Official record
Conditions
Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
Interventions
CTX001
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years to 35 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
6
States / cities
Palo Alto, California • Chicago, Illinois • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Results available

Biotin-RBC Transfusion in SCD

NCT04426591
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Biotin Labeled Red Blood Cells, Pathogen-reduced Biotin Labeled Red Blood Cells
Drug · Device
Lead sponsor
Marianne Yee
Other
Eligibility
2 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Not applicable Interventional Results available

Improving Self-Management in Adolescents With Sickle Cell Disease

NCT02851615
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
SCThrive Intervention for Adolescents with SCD
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
13 Years to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Voxelotor CYP and Transporter Cocktail Interaction Study

NCT05981365
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor, Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, Metformin, Furosemide, Rosuvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 15, 2026, 8:53 AM EDT